Fanny Windenberger

Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor

C. García-echeverría, C. Lengauer, L. Vincent, 2016, Molecular Cancer Therapeutics.

Concomitant Inhibition of PI 3 K b andBRAForMEK in PTEN-De fi cient / BRAF-Mutant Melanoma Treatment : Preclinical Assessment of SAR 260301 Oral PI 3 K b-Selective Inhibitor H el

C. García-echeverría, C. Lengauer, L. Vincent, 2016 .

TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC

L. Debussche, S. Sidhu, J. Moll, 2023, Pharmaceuticals.

Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor

C. García-echeverría, C. Lengauer, L. Vincent, 2016, Molecular Cancer Therapeutics.